Concord Drugs Ltd vs ZYDUS LIFESCIENCES LTD

A side-by-side comparison of Concord Drugs Ltd (CONCORDDRUGSLTD) and ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, ZYDUS LIFESCIENCES LTD leads CONCORDDRUGSLTD vs ZYDUSLIFE on 12 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

89.80
P/E ratio
22.83
1.95
P/B ratio
4.09
0.00%
Dividend yield
0.09%
₹0.30
EPS
₹50.09

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

2.52%
Return on equity
21.20%
4.73%
Return on capital
21.00%
10.21%
EBITDA margin
31.00%
0.81%
Net margin
18.87%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

15.34%
Revenue CAGR (3Y)
16.35%
5.67%
Profit CAGR (3Y)
34.80%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹100 Cr
Market cap
₹1.15L Cr
₹37 Cr
Revenue
₹27,148 Cr
₹0 Cr
Net profit
₹5,124 Cr
0.24
Debt / equity
0.46
Concord Drugs Ltd
  • + ["Company has reduced debt.", "Company is expected to give good quarter"]
  • ["Though the company is reporting repeated profits, it is not paying out dividend", "Company has low interest coverage ratio.", "The company has delivered a poor sales growth of 8.12% over past five years.", "Company has a low return on equity of 1.63% over last 3 years."]
ZYDUS LIFESCIENCES LTD
  • + ["Company has delivered good profit growth of 18.8% CAGR over last 5 years"]
Concord Drugs Ltd full analysis ZYDUS LIFESCIENCES LTD full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

Concord Drugs Ltd vs ZYDUS LIFESCIENCES LTD: Share Price, Valuation & Which to Buy | DocStoX